Newsroom
latest news from ose
and across our portfolio
Featured News
All News
Portfolio NewsVaccitechVaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis BPortfolio NewsVaccitechVaccitech’s VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile in Women with HPVPortfolio NewsVaccitechVaccitech appoints industry veteran, Nadège Pelletier, Ph.D., as Chief Scientific OfficerPortfolio NewsVaccitechVaccitech to host KOL webinar on the SNAPvax™ platform for inducing tolerance to treat celiac and other autoimmune diseasesPortfolio NewsVaccitechVaccitech reports third quarter 2022 financial results and recent corporate developmentsPortfolio NewsVaccitechVaccitech reports second quarter 2022 financial results and recent corporate developmentsPortfolio NewsVaccitechVaccitech’s VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1Portfolio NewsVaccitechArbutus and Vaccitech dose first patient in Phase 2a clinical trial combining therapies for the treatment of chronic hepatitis B virusPortfolio NewsVaccitechVaccitech announces notification of milestone and royalty revenue relating to sales of VaxzevriaPortfolio NewsVaccitechVaccitech reports full-year 2021 financial results and recent corporate developmentsPortfolio NewsVaccitechVaccitech announces Cancer Research UK dose first patient in Phase I/IIa trial of lung cancer immunotherapy vaccinePortfolio NewsVaccitechVaccitech acquires Avidea Technologies to expand product pipeline and strengthen scientific leadership in immunotherapies and vaccinesPortfolio NewsVaccitechVaccitech reports promising interim efficacy analysis in Phase 1b/2a clinical study in chronic HBVPortfolio NewsVaccitechVaccitech reports third quarter 2021 financial results and recent corporate developmentsPortfolio NewsVaccitechVaccitech’s VTP-300 was well-tolerated and induced T cells against all targeted HBV antigens in both healthy volunteers and patients with chronic HBV infection in interim analysesPortfolio NewsVaccitechVaccitech announces publication of second Phase 1 clinical trial results of ChAdOx1 vaccine in development for the MERS coronavirusPortfolio NewsVaccitechArbutus Biopharma and Vaccitech announce clinical trial collaboration for chronic hepatitis B virus infectionPortfolio NewsVaccitechVaccitech announces closing of $110.5 million initial public offeringPortfolio NewsVaccitechVaccitech announces pricing of initial public offeringPortfolio NewsVaccitechVaccitech appoints Joseph Scheeren, PharmD, to its Board of DirectorsPortfolio NewsVaccitechVaccitech doses first patient in HPV001, a Phase 1/2 clinical trial of VTP-200 immunotherapeutic for high-risk persistent HPV infectionPortfolio NewsVaccitechVaccitech completes $168 million Series B financing to advance three clinical programs through Phase 2 resultsPortfolio NewsVaccitechVaccitech appoints two independent board directorsPortfolio NewsVaccitechVaccitech doses first patient in HBV002, a Phase 1b/2a clinical trial of VTP-300 immunotherapeutic candidate for chronic HBV patientsOSE NewsVaccitechBreakthrough for Oxford's covid vaccine, co-invented by VaccitechPortfolio NewsVaccitechVaccitech expands management team with new hires, including CMO and CFOPortfolio NewsVaccitechVaccitech and Oxford University announce landmark partnership with AstraZeneca for the development and large-scale distribution of the COVID-19 vaccine candidate